Abstract
Paracrine and juxtacrine signaling via proteins expressed on the cell surface are an integral part of metazoan biology. More than one-half billion years ago epidermal growth factor (EGF) and its cognate receptor formed a functional binding partnership, which has been conserved through evolution in essentially all eubilaterate members of the animal kingdom. Early chordates spawned offspring of these seminal genes to begin the creation of new gene families and an expanded cell-cell signaling network, which included the Neuregulin (NRG) ligands and the erbB receptors. First appearance of ancestral NRG, represented in a NRG4-like gene in the lancelet Branchiostoma floridae, appears to have: 1) occurred in the common chordate ancestor prior to the divergence of lancelets (amphioxus), and; 2) antedated the formation of the receptor gene family. Orthologues of NRG1 and multiple erbB receptors found in the sea lamprey Petromyzon marinus suggest that several key events, which were required to expand and diversify these gene families, occurred in the common ancestor of agnathostomes and jawed vertebrates. These important inventions surely played major roles in the acquisition of multiple apomorphic features of the emerging vertebrate lineage.
Keywords: Binding, erbB receptor, lamprey, lancelet.
Current Pharmaceutical Design
Title:Neuregulin Signaling in Pieces-Evolution of the Gene Family
Volume: 20 Issue: 30
Author(s): Mark A. Marchionni
Affiliation:
Keywords: Binding, erbB receptor, lamprey, lancelet.
Abstract: Paracrine and juxtacrine signaling via proteins expressed on the cell surface are an integral part of metazoan biology. More than one-half billion years ago epidermal growth factor (EGF) and its cognate receptor formed a functional binding partnership, which has been conserved through evolution in essentially all eubilaterate members of the animal kingdom. Early chordates spawned offspring of these seminal genes to begin the creation of new gene families and an expanded cell-cell signaling network, which included the Neuregulin (NRG) ligands and the erbB receptors. First appearance of ancestral NRG, represented in a NRG4-like gene in the lancelet Branchiostoma floridae, appears to have: 1) occurred in the common chordate ancestor prior to the divergence of lancelets (amphioxus), and; 2) antedated the formation of the receptor gene family. Orthologues of NRG1 and multiple erbB receptors found in the sea lamprey Petromyzon marinus suggest that several key events, which were required to expand and diversify these gene families, occurred in the common ancestor of agnathostomes and jawed vertebrates. These important inventions surely played major roles in the acquisition of multiple apomorphic features of the emerging vertebrate lineage.
Export Options
About this article
Cite this article as:
Marchionni A. Mark, Neuregulin Signaling in Pieces-Evolution of the Gene Family, Current Pharmaceutical Design 2014; 20 (30) . https://dx.doi.org/10.2174/1381612819666131125152146
DOI https://dx.doi.org/10.2174/1381612819666131125152146 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oxygen Sensing, Cardiac Ischemia, HIF-1α and Some Emerging Concepts
Current Cardiology Reviews Reactive Oxygen Species Formation by Polymorphonuclear Cells and Mononuclear Cells as a Risk Factor of Cardiovascular Diseases
Current Pharmaceutical Biotechnology Non Pregnant Human Uterus as Source of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy A PHACES Syndrome Unmasked by Propranolol Interruption in a Tetralogy of Fallot Patient: Case Report and Extensive Review on New Indications of Beta Blockers
Current Medicinal Chemistry The Role of Cnidaria in Drug Discovery. A Review on CNS Implications and New Perspectives
Recent Patents on CNS Drug Discovery (Discontinued) Present Drug Therapy of Demyelinating Disorders
Current Drug Therapy Membrane Disrupting Lytic Peptides for Cancer Treatments
Current Pharmaceutical Design Renoprotective Potency of Heme Oxygenase-1 Induction in Rat Renal Ischemia-Reperfusion
Inflammation & Allergy - Drug Targets (Discontinued) Cardiovascular Implantable Electronic Device Infections: Risk Scoring and Role of Antibiotic Envelope in Prevention
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Forced Degradation Study of Quinapril by UPLC-DAD and UPLC/ MS/MS: Identification of By-products and Development of Degradation Kinetics
Current Pharmaceutical Analysis Insights Into the Role of microRNAs in Cardiac Diseases: From Biological Signalling to Therapeutic Targets
Cardiovascular & Hematological Agents in Medicinal Chemistry Menopausal Hormone Therapy and Cardiovascular Risk: Where are we Now?
Current Vascular Pharmacology Role of ERK1/2 Activation In Thrombin-Induced Vascular Smooth Muscle Cell Hypertrophy
Current Hypertension Reviews Hydrogen Sulphide in Heart and Systemic Circulation
Inflammation & Allergy - Drug Targets (Discontinued) Nebivolol: More Than a Highly Selective Beta Blocker
Recent Patents on Cardiovascular Drug Discovery The Oxygen Therapy
Current Medicinal Chemistry Halting Arterial Aging in Patients with Cardiovascular Disease: Hypolipidemic and Antihypertensive Therapy
Current Pharmaceutical Design Targeting the PI3K/Akt/mTOR Axis by Apigenin for Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Short-term RR-Interval Power Spectral Analysis as a New Tool to Stratify the Risk of Sudden Death in Various Cardiovascular Conditions
Vascular Disease Prevention (Discontinued) Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein 1: Recent Developments Concerning Substrates and Inhibitors of a Promising Therapeutic Target
Current Medicinal Chemistry